Literature DB >> 9926938

Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma.

K Wimmer1, X X Zhu, B J Lamb, R Kuick, P F Ambros, H Kovar, D Thoraval, S Motyka, J R Alberts, S M Hanash.   

Abstract

Substantial evidence implicates amplification of the N-myc gene with aggressive tumor growth and poor outcome in neuroblastoma. However some evidence suggests that this gene alone is not the sole determinant of outcome in N-myc amplified tumors. We have searched for genes that co-amplify with N-myc in neuroblastoma by means of two-dimensional analysis of genomic restriction digests. Using this approach, we have identified and cloned a novel genomic fragment which is co-amplified with N-myc in neuroblastomas. This fragment was mapped in close vicinity to N-myc on chromosome arm 2p24. It was amplified in 5/8 N-myc amplified neuroblastoma cell lines and in 9/13 N-myc amplified tumors. Using a PCR-based approach we isolated a 4.5 kb c-DNA sequence that is partly contained in the genomic fragment. The open reading frame of the cDNA encodes a predicted protein of 1353 amino acids (aa). The homology of the predicted protein, which we designated NAG (neuroblastoma amplified gene), to a C. elegans protein of as yet unknown function, and its ubiquitous expression suggest that NAG may serve an essential function. By Northern blot analysis we showed that amplification of the cloned gene correlates with over-expression in neuroblastoma cell lines. Amplification and consequent over-expression of NAG may, therefore, contribute to the phenotype of a subset of neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9926938     DOI: 10.1038/sj.onc.1202287

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Virtual genome scan: a tool for restriction landmark-based scanning of the human genome.

Authors:  J M Rouillard; A E Erson; R Kuick; J Asakawa ; K Wimmer; M Muleris; E M Petty; S Hanash
Journal:  Genome Res       Date:  2001-08       Impact factor: 9.043

Review 2.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.

Authors:  Rong Wu; Lin Lin; David G Beer; Lora H Ellenson; Barbara J Lamb; Jean-Marie Rouillard; Rork Kuick; Samir Hanash; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.

Authors:  M C Frühwald; M S O'Dorisio; L J Rush; J L Reiter; D J Smiraglia; G Wenger; J F Costello; P S White; R Krahe; G M Brodeur; C Plass
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

5.  Identification of the neuroblastoma-amplified gene product as a component of the syntaxin 18 complex implicated in Golgi-to-endoplasmic reticulum retrograde transport.

Authors:  Takehiro Aoki; Sarah Ichimura; Ayano Itoh; Mami Kuramoto; Takashi Shinkawa; Toshiaki Isobe; Mitsuo Tagaya
Journal:  Mol Biol Cell       Date:  2009-04-15       Impact factor: 4.138

6.  Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization.

Authors:  Ben Beheshti; Ilan Braude; Paula Marrano; Paul Thorner; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

7.  N-myc modulates expression of p73 in neuroblastoma.

Authors:  Xiaoxiang Zhu; Katharina Wimmer; Rork Kuick; Barbara J Lamb; Stephanie Motyka; Rama Jasty; Valerie P Castle; Samir M Hanash
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

8.  Mechanistic insights and identification of two novel factors in the C. elegans NMD pathway.

Authors:  Dasa Longman; Ronald H A Plasterk; Iain L Johnstone; Javier F Cáceres
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

9.  Compound heterozygous variants in NBAS as a cause of atypical osteogenesis imperfecta.

Authors:  M Balasubramanian; J Hurst; S Brown; N J Bishop; P Arundel; C DeVile; R C Pollitt; L Crooks; D Longman; J F Caceres; F Shackley; S Connolly; J H Payne; A C Offiah; D Hughes; M J Parker; W Hide; T M Skerry
Journal:  Bone       Date:  2016-10-24       Impact factor: 4.398

10.  Resolution of recurrent pediatric acute liver failure with liver transplantation in a patient with NBAS mutation.

Authors:  Duke Geem; Wenxiao Jiang; Heather B Rytting; Shanmuganathan Chandrakasan; Anand Salem; James P Stevens; Saul J Karpen; Joseph F Magliocca; Rene Romero; Dellys Soler Rodriguez
Journal:  Pediatr Transplant       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.